Cargando…

Tumor necrosis factor α-induced protein 3 (A20) is dysregulated in pediatric Crohn disease

PURPOSE: A significant feature of pediatric inflammatory bowel diseases (IBD), which include Crohn disease (CD), and ulcerative colitis (UC), is failure to suppress inflammation. The inability to regulate inflammation renders a major challenge toward establishing effective treatments in IBD. Nuclear...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zaidi, Deenaz, Huynh, Hien Q, Carroll, Matthew W, Baksh, Shairaz, Wine, Eytan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5985767/ https://www.ncbi.nlm.nih.gov/pubmed/29881302 http://dx.doi.org/10.2147/CEG.S148217

Ejemplares similares

Regulation of Nuclear Factor Kappa-Light-Chain-Enhancer of Activated B Cells (NF-κβ) in Inflammatory Bowel Diseases
por: Zaidi, Deenaz, et al.
Publicado: (2018)

Host immunoglobulin G selectively identifies pathobionts in pediatric inflammatory bowel diseases
por: Armstrong, Heather, et al.
Publicado: (2019)

RIPK2: New Elements in Modulating Inflammatory Breast Cancer Pathogenesis
por: Zare, Alaa, et al.
Publicado: (2018)

Erratum: Zare, A. et al. RIPK2: New Elements in Modulating Inflammatory Breast Cancer Pathogenesis. Cancers, 2018, 10, 184
por: Zare, Alaa, et al.
Publicado: (2018)

Novel Biomarkers for Inflammatory Bowel Disease and Colorectal Cancer: An Interplay between Metabolic Dysregulation and Excessive Inflammation
por: Salla, Mohamed, et al.
Publicado: (2023)

Early Serum Infliximab Levels in Pediatric Ulcerative Colitis
por: deBruyn, Jennifer C. C., et al.
Publicado: (2021)

The Frequency of Clinic Visits Was Not Associated with Medication Adherence or Outcome in Children with Inflammatory Bowel Diseases
por: Kluthe, Cheryl, et al.
Publicado: (2018)

Sustained Diet-Induced Remission in Pediatric Crohn’s Disease Is Associated With Kynurenine and Serotonin Pathways
por: Ghiboub, Mohammed, et al.
Publicado: (2023)

SARS-CoV-2 infection in severe pediatric Crohn's disease. What about anti-tumor necrosis factor α therapy?
por: Bardasi, Giulia, et al.
Publicado: (2020)

RASSF1 Polymorphisms in Cancer
por: Gordon, Marilyn, et al.
Publicado: (2012)

Modulator of Apoptosis 1: A Highly Regulated RASSF1A-Interacting BH3-Like Protein
por: Law, Jennifer, et al.
Publicado: (2012)

Continued Postoperative Use of Tumor Necrosis Factor-α Inhibitors for the Prevention of Crohn’s Disease Recurrence
por: Yu, Jongwook, et al.
Publicado: (2022)

The Genetics of Postoperative Recurrence in Crohn Disease: A Systematic Review, Meta-analysis, and Framework for Future Work
por: Dang, Jerry T, et al.
Publicado: (2021)

A14 TRANSABDOMINAL BOWEL ULTRASOUND AND CLINICAL OUTCOMES OVER ONE YEAR IN CHILDREN WITH NEWLY DIAGNOSED CROHN’S DISEASE
por: Hudson, A, et al.
Publicado: (2023)

Is top-down therapy a more effective alternative to conventional step-up therapy for Crohn’s disease?
por: Tsui, Jonathan Jenkin, et al.
Publicado: (2018)

The Long-Term Effect of Early Anti-Tumor Necrosis Factor on Restoration of Growth in Pediatric Crohn’s Disease
por: Shim, Jung Ok, et al.
Publicado: (2018)

Growth and Adult Height in Patients with Crohn's Disease Treated with Anti-Tumor Necrosis Factor α Antibodies
por: Bamberger, Sarah, et al.
Publicado: (2016)

Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn's disease
por: Hiraoka, Sakiko, et al.
Publicado: (2018)

A Series of Genes for Predicting Responses to Anti-Tumor Necrosis Factor α Therapy in Crohn’s Disease
por: Nie, Kai, et al.
Publicado: (2022)

Tumor Necrosis Factor’s Pathway in Crohn’s Disease: Potential for Intervention
por: Pagnini, Cristiano, et al.
Publicado: (2021)

Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: systematic review and meta-analysis
por: Kawalec, Paweł, et al.
Publicado: (2013)

Tofacitinib for the treatment of tumor necrosis factor-α inhibitor refractory esophageal Crohn’s disease: a case report
por: Nathoo, Sunina, et al.
Publicado: (2016)

Rare and Serious Adverse Effects of Anti-Tumor Necrosis Factor-Alpha (TNF-α) Agents in Crohn’s Disease
por: Kim, Sun, et al.
Publicado: (2021)

Comparison of mucosa-associated microbiota in Crohn’s disease patients with and without anti-tumor necrosis factor-α therapy
por: Fukushima, Shinya, et al.
Publicado: (2022)

Dual Biologic Therapy in a Patient With Niemann-Pick Type C and Crohn Disease: A Case Report and Literature Review
por: Hudson, Alexandra S., et al.
Publicado: (2022)

Calreticulin inhibits commitment to adipocyte differentiation
por: Szabo, Eva, et al.
Publicado: (2008)

RASSF Family Proteins
por: Clark, Geoffrey J., et al.
Publicado: (2012)

Calreticulin inhibits commitment to adipocyte differentiation
por: Szabo, Eva, et al.
Publicado: (2015)

The Na(+) /H(+) exchanger (NHE1) as a novel co-adjuvant target in paclitaxel therapy of triple-negative breast cancer cells
por: Amith, Schammim Ray, et al.
Publicado: (2014)

The Tumor Suppressor Gene, RASSF1A, Is Essential for Protection against Inflammation -Induced Injury
por: Gordon, Marilyn, et al.
Publicado: (2013)

Correction: The Tumor Suppressor Gene, RASSF1A, Is Essential for Protection against Inflammation -Induced Injury
por: Gordon, Marilyn, et al.
Publicado: (2014)

Correction: The Tumor Suppressor Gene, RASSF1A, Is Essential for Protection against Inflammation -Induced Injury
por: Gordon, Marilyn, et al.
Publicado: (2015)

Albumin-to-Globulin Ratio at 1 Year after Anti-Tumor Necrosis Factor α Therapy Can Serve as a Prognostic Biomarker in Pediatric Crohn’s Disease Patients
por: Kim, Eun Sil, et al.
Publicado: (2022)

Cost-Effectiveness Analysis of Crohn’s Disease Treatment with Vedolizumab and Ustekinumab After Failure of Tumor Necrosis Factor-α Antagonist
por: Holko, Przemysław, et al.
Publicado: (2018)

Long-term clinical and real-world experience with Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
por: Otake, Haruka, et al.
Publicado: (2022)

Systematic review and meta-analysis on the association of tuberculosis in Crohn’s disease patients treated with tumor necrosis factor-α inhibitors (Anti-TNFα)
por: Cao, Brent L, et al.
Publicado: (2018)

Effects of visceral adipose tissue on anti-tumour necrosis factor-α in Crohn’s disease
por: Li, Kangrong, et al.
Publicado: (2023)

Editorial: Pediatric Inflammatory Bowel Diseases: Looking to the Future
por: Wine, Eytan, et al.
Publicado: (2020)

Infliximab vs adalimumab: Points to consider when selecting anti-tumor necrosis factor agents in pediatric patients with Crohn’s disease
por: Kim, Eun Sil, et al.
Publicado: (2023)

Long-term prognosis of Japanese patients with biologic-naïve Crohn’s disease treated with anti-tumor necrosis factor-α antibodies
por: Moroi, Rintaro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ia51qk0nnqvd5bfqojk20lmdg3